Early HDAC inhibitors, such as vorinostat and panobinostat, exhibited higher effects than anticipated in a single or combined administration in preclinical models of various drug-resistant cancers, thereby providing a sufficient rationale to initiate clinical trials. The gene discussed is HDAC9; the disease is cancer.